全文获取类型
收费全文 | 3505篇 |
免费 | 270篇 |
国内免费 | 17篇 |
专业分类
耳鼻咽喉 | 20篇 |
儿科学 | 63篇 |
妇产科学 | 80篇 |
基础医学 | 572篇 |
口腔科学 | 17篇 |
临床医学 | 401篇 |
内科学 | 788篇 |
皮肤病学 | 33篇 |
神经病学 | 377篇 |
特种医学 | 129篇 |
外科学 | 494篇 |
综合类 | 5篇 |
一般理论 | 6篇 |
预防医学 | 170篇 |
眼科学 | 38篇 |
药学 | 217篇 |
中国医学 | 9篇 |
肿瘤学 | 373篇 |
出版年
2024年 | 3篇 |
2023年 | 23篇 |
2022年 | 27篇 |
2021年 | 120篇 |
2020年 | 55篇 |
2019年 | 96篇 |
2018年 | 120篇 |
2017年 | 93篇 |
2016年 | 86篇 |
2015年 | 112篇 |
2014年 | 153篇 |
2013年 | 202篇 |
2012年 | 276篇 |
2011年 | 298篇 |
2010年 | 175篇 |
2009年 | 151篇 |
2008年 | 256篇 |
2007年 | 234篇 |
2006年 | 210篇 |
2005年 | 233篇 |
2004年 | 182篇 |
2003年 | 182篇 |
2002年 | 151篇 |
2001年 | 39篇 |
2000年 | 44篇 |
1999年 | 46篇 |
1998年 | 36篇 |
1997年 | 19篇 |
1996年 | 19篇 |
1995年 | 12篇 |
1994年 | 12篇 |
1993年 | 9篇 |
1992年 | 16篇 |
1991年 | 13篇 |
1990年 | 10篇 |
1989年 | 9篇 |
1988年 | 5篇 |
1987年 | 8篇 |
1986年 | 9篇 |
1985年 | 3篇 |
1979年 | 6篇 |
1976年 | 3篇 |
1975年 | 3篇 |
1971年 | 4篇 |
1969年 | 2篇 |
1966年 | 3篇 |
1939年 | 2篇 |
1935年 | 2篇 |
1934年 | 3篇 |
1933年 | 2篇 |
排序方式: 共有3792条查询结果,搜索用时 15 毫秒
81.
82.
83.
84.
Lioure B Béné MC Pigneux A Huynh A Chevallier P Fegueux N Blaise D Witz B Delain M Cornillon J Luquet I Blanchet O Cornillet-Lefebvre P Carré M Hunault M Larosa F Lamy T Randriamalala E Ojeda-Uribe M Berthou C Fornecker L Harousseau JL Bouscary D Ifrah N Cahn JY;GOELAMS 《Blood》2012,119(12):2943-2948
The LAM2001 phase 3 trial, involving 832 patients with acute myeloid leukemia (AML; median: 46 years) proposed HLA-identical sibling allograft HSCT for all patients with an identified donor. The trial compared reduced-intensity conditioning (RIC) for patients older than 50 years of age (N = 47) and myeloablative conditioning for younger patients (N = 117). BM HSCT was performed in the younger patients, while the older ones received a consolidation course, followed by peripheral blood allo-HSCT using RIC. The incidence of grade II-IV acute GVHD, was 51.9% (95% confidence interval [CI]: 42.1-61.8) and 11.3% (1.6-21.2) after myeloablative or RIC, respectively (P < .0001) and that of chronic GVHD 45.8% (95% CI: 34.8-56.7) and 41.7% (24.7-58.6; NS). Cumulative incidence of nonrelapse mortality at 108 months was 15.8% (95% CI: 9.8-23.2) for myeloablative, and 6.5% (0.2-16.2) for RIC (NS). CI of relapse at 108 months was 21.7% (95% CI: 13.9-28.6) and 28.6% (16.5-43.4; NS). Overall survival at 108 months was 63.4% (95% CI: 54.6-72.2) and 65.8% (52.2-72.2), respectively, after myeloablative or RIC (NS). RIC peripheral blood stem cell allo-HSCT is prospectively feasible for patients between the ages of 51 and 60 years without excess of relapse or nonrelapse mortality, and compares favorably with myeloablative marrow allo-HSCT proposed to younger patients. 相似文献
85.
Terrier B Krastinova E Marie I Launay D Lacraz A Belenotti P de Saint-Martin L Quemeneur T Huart A Bonnet F Le Guenno G Kahn JE Hinschberger O Rullier P Diot E Lazaro E Bridoux F Zénone T Carrat F Hermine O Léger JM Mariette X Senet P Plaisier E Cacoub P 《Blood》2012,119(25):5996-6004
Data on the clinical spectrum and therapeutic management of noninfectious mixed cryoglobulinemia vasculitis (CryoVas) in the era of hepatitis C virus screening are lacking. We analyzed data from 242 patients with noninfectious mixed CryoVas included in the French multicenter CryoVas survey. Baseline manifestations were purpura (75%), peripheral neuropathy (52%), arthralgia or arthritis (44%), glomerulonephritis (35%), cutaneous ulcers (16%), and cutaneous necrosis (14%). A connective tissue disease was diagnosed in 30% and B-cell non-Hodgkin lymphoma in 22%, whereas the CryoVas was considered to be essential in 48%. With the use of Cox-marginal structural models, rituximab plus corticosteroids showed the greater therapeutic efficacy compared with corticosteroids alone and alkylating agents plus corticosteroids to achieve complete clinical, renal, and immunologic responses and a prednisone dosage < 10 mg/d at 6 months. However, this regimen was also associated with severe infections, particularly when high doses of corticosteroids were used, whereas death rates did not differ between the therapeutic regimens. The role of each of these strategies remains to be defined in well-designed randomized controlled trials. 相似文献
86.
87.
Fabrice Airaud S��bastien K��ry Isabelle Valo Ingrid Maury Dominique Bonneau Olivier Ingster St��phane Bezieau 《World journal of gastroenterology : WJG》2012,18(39):5635-5639
We describe a patient with a Homo sapiens mutL homolog 1 (MLH1)-associated Lynch syndrome with previous diagnoses of two distinct primary cancers: a sigmoid colon cancer at the age of 39 years, and a right colon cancer at the age of 50 years. The mutation identified in his blood and buccal cells, c.1771delG, p.Asp591Ilefs*25, appears to be a de novo event, as it was not transmitted by either of his parents. This type of de novo event is rare in MLH1 as only three cases have been reported in the literature so far. Furthermore, the discordant results observed between replication error phenotyping and immunohistochemistry highlight the importance of the systematic use of both pre-screening tests in the molecular diagnosis of Lynch syndrome. 相似文献
88.
89.
Sokol H Beaugerie L Maynadié M Laharie D Dupas JL Flourié B Lerebours E Peyrin-Biroulet L Allez M Simon T Carrat F Brousse N;for the CESAME Study Group 《Inflammatory bowel diseases》2012,18(11):2063-2071
BACKGROUND: It remains to be shown whether inflammatory bowel disease (IBD) is associated with an increased risk of primary intestinal lymphoproliferative disorders (PILD). We assessed this risk in the CESAME French nationwide prospective observational cohort. METHODS: In all, 680 gastroenterologists enrolled 19,486 patients with IBD (Crohn's disease in 60.3%) from May 2004 to June 2005. Follow-up ended on 31 December 2007. Available biopsy samples and surgical specimens from patients with PILD (n = 14) were centralized for review. The reference incidence of PILD in the general population was obtained from the C?te d'Or registry and was used as a comparator to assess the standardized incidence ratio (SIR). The influence of thiopurine exposure was explored in a nested case-control study. RESULTS: In the CESAME population the crude incidence of PILD was 0.12/1000 patient-years, with a corresponding SIR of 17.51 (95% confidence interval [CI], 6.43-38.11; P < 0.0001). The risk was highest in patients exposed to thiopurines (SIR 49.52, 95% CI 13.49-126.8; P < 0.0001), while it did not reach statistical significance in patients na?ve to thiopurines (SIR 4.83, 95% CI, 0.12-26.91; P = 0.37). The odds ratio associated with ongoing thiopurine exposure (vs. na?ve) was 2.97 (95% CI, 0.30-infinity; P = 0.38). All 14 cases of PILD were non-Hodgkin's B-cell LD, 78.6% occurred in males, 85.7% arose in IBD lesions, and 45.5% were Epstein-Barr virus-positive. Eleven cases occurred in patients with Crohn's disease. Mean (SD) age at PILD diagnosis was 55.1 (5.6) years and the median time since IBD onset was 8.0 years (interquartile range, 3.0-15.8). CONCLUSIONS: Patients with IBD have an increased risk of developing PILD. (Inflamm Bowel Dis 2012;). 相似文献
90.
Qian Wang‐Lopez PhD Student Catherine Abrial PhD Eloïse Planchat PhD Marie‐Ange Mouret‐Reynier MD Hervé Cure MD PhD Pr Pierre Gimbergues MD Pascale Dubray‐Longeras MD Emilie Gadea PhD Student Fabrice Kwiatkowski MS Frédérique Penault‐Llorca MD PhD Pr Philippe Chollet MD PhD Pr Xavier Durando MD PhD 《The breast journal》2013,19(4):448-450